Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. The companys patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of various existing and new pharmaceuticals. It has a pipeline of 15 products in various stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. The companys lead generic product under development includes generic Focalin XR (dexmethylphenidate hydrochloride), an extended-release capsule for the treatment of attention deficit hyperactivity disorder. Intellipharmaceutics has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. In addition, the company has two generic products filed with the FDA, including a generic of Effexor XR (venlafaxine hydrochloride) and Protonix (delayed release pantoprazole sodium). Its lead non-generic product under development is Rexista oxycodone, an abuse- and alcohol-resistant controlled-release oral oxycodone formulation for the relief of pain. The company also has products under late stage development, which consist of venlafaxine hydrochloride, an extended-release capsule for the treatment of symptoms of depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder; and carvedilol phosphate, an extended-release capsule for the treatment of hypertension and heart conditions. The company was formerly known as IntelliPharmaCeutics Ltd. and changed its name to Intellipharmaceutics International Inc. in October 2009. IntelliPharmaCeutics International Inc. was founded in 1998 and is based in Toronto, Canada.
IntelliPharmaCeutics International Inc.
30 Worcester Road
Toronto, ON M9W 5X2
Shares Outstanding: 10.91M